President Biden hosted the Merck and Johnson & Johnson CEOs at a press conference today. "The partnership between Johnson & Johnson and Merck proves we can do big things, important things in our country," Biden said. For access to live and exclusive video from CNBC subscribe to CNBC PRO: [ Ссылка ]

The U.S. plans to buy 100 million additional doses of Johnson & Johnson’s Covid-19 vaccine, the Biden administration announced Wednesday.

President Joe Biden is expected to discuss the plans later Wednesday during a White House meeting with executives from J&J and Merck.

J&J currently has a deal with the U.S. government to provide 100 million doses by the end of June. The federal government shipped out nearly 3.9 million doses of the single-shot vaccine last week and says it plans to distribute 16 million more by the end of this month.

The new order allows “the president to plan for the future in the latter part of the year,” Andy Slavitt, a senior advisor to Biden’s Covid response team, said during a White House news briefing. “This is wartime,” Slavitt said, adding more doses gives the administration “more flexibility for our upcoming needs.”

In a statement, J&J noted that the government’s initial deal of 100 million doses, worth $1 billion, in August gave it the option to purchase additional shots under a subsequent agreement.

“We look forward to any future discussions with the U.S. Government and to participating in the event at the White House later today,” the company said in a statement.

The announcement comes as the administration works to ramp up production of J&J’s vaccine after it learned earlier in the year that the company had fallen behind in output.

The Food and Drug Administration on Feb. 27 authorized J&J’s vaccine for use in people 18 and older. Unlike Pfizer’s and Moderna’s vaccines, J&J’s one-dose regimen eliminates the need for patients to return for a second dose, and it can be stored at refrigerator temperatures for months.

The New York Times first reported in January that unexpected manufacturing delays would lead to a reduced initial supply of J&J’s drug if it were given emergency authorization.

Last week, Biden announced that pharmaceutical giant Merck would help make J&J’s Covid vaccine. Under the arrangement, Merck will dedicate two facilities in the U.S. to J&J’s vaccine. One will make the vaccine and the other will provide “fill-finish” services, when the vaccine is placed in vials.

The Department of Health and Human Services said the U.S. will use the Defense Production Act to give Merck $105 million to convert, upgrade and equip the company’s facilities to the standards necessary to safely manufacture the vaccine.

» Subscribe to CNBC TV: [ Ссылка ]
» Subscribe to CNBC: [ Ссылка ]
» Subscribe to CNBC Classic: [ Ссылка ]

Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.

The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: [ Ссылка ]

Connect with CNBC News Online
Get the latest news: [ Ссылка ]
Follow CNBC on LinkedIn: [ Ссылка ]
Follow CNBC News on Facebook: [ Ссылка ]
Follow CNBC News on Twitter: [ Ссылка ]
Follow CNBC News on Instagram: [ Ссылка ]

[ Ссылка ]

#CNBC
#CNBCTV

свернуть